Kennondale Capital Management LLC Acquires New Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Kennondale Capital Management LLC purchased a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 151,280 shares of the biotechnology company's stock, valued at approximately $755,000. Kennondale Capital Management LLC owned 0.25% of Aldeyra Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. State Street Corp increased its position in shares of Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company's stock valued at $5,249,000 after buying an additional 16,188 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock worth $2,571,000 after purchasing an additional 295,864 shares during the period. Barclays PLC grew its holdings in Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock worth $353,000 after purchasing an additional 48,313 shares during the period. SG Americas Securities LLC grew its holdings in Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,822 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new stake in Aldeyra Therapeutics in the fourth quarter worth about $234,000. Hedge funds and other institutional investors own 59.71% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday, March 3rd.

Aldeyra Therapeutics Stock Performance

ALDX traded down $0.14 during midday trading on Friday, reaching $6.58. The company's stock had a trading volume of 675,335 shares, compared to its average volume of 480,604. The stock's 50-day moving average is $5.93 and its 200-day moving average is $5.51. Aldeyra Therapeutics, Inc has a 1 year low of $2.85 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.30). As a group, equities research analysts expect that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.